HALO — Halozyme Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $7.30bn
- $9.30bn
- $1.40bn
Annual cashflow statement for Halozyme Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 403 | 202 | 282 | 444 | 317 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 45.4 | 34.3 | 26.3 | 42.4 | 398 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.74 | -86 | -38.7 | -89.3 | -152 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 299 | 240 | 389 | 479 | 652 |
| Capital Expenditures | -1.46 | -4.81 | -15.3 | -10.7 | -295 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -405 | -482 | -81.6 | -252 | -251 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -406 | -487 | -96.9 | -263 | -546 |
| Financing Cash Flow Items | -0.424 | -76.2 | 0 | 0 | -4.94 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 77.9 | 362 | -408 | -219 | -85.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -29 | 115 | -116 | -2.52 | 20.6 |